LAG3 and hepatocellular carcinoma: The authors proposed that the transfer therapy of allogeneic Vδ2+ γδ T cells, expanded from peripheral blood mononuclear cells of healthy donors, could complement the functional loss observed in intratumoral γδ T cells and serve as a new treatment strategy in HCC patients, especially when combined with LAG3 inhibitor.